Cargando…
Breast cancer brain metastasis: Current evidence and future directions
Breast cancer is the most common cancer in women and the second leading cause of cancer‐related deaths after lung cancer. Metastasis of the central nervous system is a terrible event for breast cancer patients, affecting their survival and quality of life. Compared with hormone receptor‐positive/hum...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883555/ https://www.ncbi.nlm.nih.gov/pubmed/35822637 http://dx.doi.org/10.1002/cam4.5021 |
_version_ | 1784879534853586944 |
---|---|
author | Sun, Hongna Xu, Junnan Dai, Shuang Ma, Yiwen Sun, Tao |
author_facet | Sun, Hongna Xu, Junnan Dai, Shuang Ma, Yiwen Sun, Tao |
author_sort | Sun, Hongna |
collection | PubMed |
description | Breast cancer is the most common cancer in women and the second leading cause of cancer‐related deaths after lung cancer. Metastasis of the central nervous system is a terrible event for breast cancer patients, affecting their survival and quality of life. Compared with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative breast cancer patients, brain metastases are more likely to affect patients with triple‐negative breast cancer and human epidermal growth factor receptor 2‐positive breast cancer. The treatment of breast cancer has improved greatly in the last two decades. However, brain metastases from breast cancer remain the leading cause of morbidity and mortality. Patients with breast cancer brain metastasis have been in an inferior position due to the lack of clinical research in this field, and they are often explicitly excluded from almost all clinical trials. The occurrence and progression of brain metastases will result in severe cognitive impairment and adverse physical consequences, so we must have a good understanding of the molecular mechanisms of breast cancer brain metastasis. In this article, we have retrieved the latest literature of molecules and pathways associated with breast cancer brain metastasis, summarized common therapy strategies, and discussed the prospects and clinical implications of targeting the molecules involved. |
format | Online Article Text |
id | pubmed-9883555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98835552023-01-31 Breast cancer brain metastasis: Current evidence and future directions Sun, Hongna Xu, Junnan Dai, Shuang Ma, Yiwen Sun, Tao Cancer Med REVIEWS Breast cancer is the most common cancer in women and the second leading cause of cancer‐related deaths after lung cancer. Metastasis of the central nervous system is a terrible event for breast cancer patients, affecting their survival and quality of life. Compared with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative breast cancer patients, brain metastases are more likely to affect patients with triple‐negative breast cancer and human epidermal growth factor receptor 2‐positive breast cancer. The treatment of breast cancer has improved greatly in the last two decades. However, brain metastases from breast cancer remain the leading cause of morbidity and mortality. Patients with breast cancer brain metastasis have been in an inferior position due to the lack of clinical research in this field, and they are often explicitly excluded from almost all clinical trials. The occurrence and progression of brain metastases will result in severe cognitive impairment and adverse physical consequences, so we must have a good understanding of the molecular mechanisms of breast cancer brain metastasis. In this article, we have retrieved the latest literature of molecules and pathways associated with breast cancer brain metastasis, summarized common therapy strategies, and discussed the prospects and clinical implications of targeting the molecules involved. John Wiley and Sons Inc. 2022-07-13 /pmc/articles/PMC9883555/ /pubmed/35822637 http://dx.doi.org/10.1002/cam4.5021 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | REVIEWS Sun, Hongna Xu, Junnan Dai, Shuang Ma, Yiwen Sun, Tao Breast cancer brain metastasis: Current evidence and future directions |
title | Breast cancer brain metastasis: Current evidence and future directions |
title_full | Breast cancer brain metastasis: Current evidence and future directions |
title_fullStr | Breast cancer brain metastasis: Current evidence and future directions |
title_full_unstemmed | Breast cancer brain metastasis: Current evidence and future directions |
title_short | Breast cancer brain metastasis: Current evidence and future directions |
title_sort | breast cancer brain metastasis: current evidence and future directions |
topic | REVIEWS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883555/ https://www.ncbi.nlm.nih.gov/pubmed/35822637 http://dx.doi.org/10.1002/cam4.5021 |
work_keys_str_mv | AT sunhongna breastcancerbrainmetastasiscurrentevidenceandfuturedirections AT xujunnan breastcancerbrainmetastasiscurrentevidenceandfuturedirections AT daishuang breastcancerbrainmetastasiscurrentevidenceandfuturedirections AT mayiwen breastcancerbrainmetastasiscurrentevidenceandfuturedirections AT suntao breastcancerbrainmetastasiscurrentevidenceandfuturedirections |